CN105307636A - 非晶形特考韦瑞制备 - Google Patents

非晶形特考韦瑞制备 Download PDF

Info

Publication number
CN105307636A
CN105307636A CN201480026785.8A CN201480026785A CN105307636A CN 105307636 A CN105307636 A CN 105307636A CN 201480026785 A CN201480026785 A CN 201480026785A CN 105307636 A CN105307636 A CN 105307636A
Authority
CN
China
Prior art keywords
methods according
octahydro
trifluoromethyl
dioxo
benzoylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026785.8A
Other languages
English (en)
Chinese (zh)
Inventor
珊莎库马尔·R·雅瓦纳吉玛特
Nk彼得·塞缪尔
约瑟夫·帕斯
谭英
丹尼斯·E·赫鲁比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Priority to CN202010516675.7A priority Critical patent/CN111635353A/zh
Publication of CN105307636A publication Critical patent/CN105307636A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480026785.8A 2013-07-19 2014-07-11 非晶形特考韦瑞制备 Pending CN105307636A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010516675.7A CN111635353A (zh) 2013-07-19 2014-07-11 非晶形特考韦瑞制备

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361856240P 2013-07-19 2013-07-19
US61/856,240 2013-07-19
PCT/US2014/046340 WO2015009566A1 (en) 2013-07-19 2014-07-11 Amorphous tecovirimat preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010516675.7A Division CN111635353A (zh) 2013-07-19 2014-07-11 非晶形特考韦瑞制备

Publications (1)

Publication Number Publication Date
CN105307636A true CN105307636A (zh) 2016-02-03

Family

ID=52346653

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026785.8A Pending CN105307636A (zh) 2013-07-19 2014-07-11 非晶形特考韦瑞制备
CN202010516675.7A Pending CN111635353A (zh) 2013-07-19 2014-07-11 非晶形特考韦瑞制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010516675.7A Pending CN111635353A (zh) 2013-07-19 2014-07-11 非晶形特考韦瑞制备

Country Status (8)

Country Link
US (3) US9670158B2 (cg-RX-API-DMAC7.html)
EP (2) EP3763702B1 (cg-RX-API-DMAC7.html)
JP (3) JP6843616B2 (cg-RX-API-DMAC7.html)
CN (2) CN105307636A (cg-RX-API-DMAC7.html)
AU (1) AU2014290333B2 (cg-RX-API-DMAC7.html)
CA (3) CA2917199C (cg-RX-API-DMAC7.html)
IL (1) IL242331B (cg-RX-API-DMAC7.html)
WO (1) WO2015009566A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107126419A (zh) * 2016-02-26 2017-09-05 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
CN115141136A (zh) * 2021-03-31 2022-10-04 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105307636A (zh) * 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053778A1 (en) * 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
US20070003516A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of poxvirus infections
US20080004452A1 (en) * 2003-06-20 2008-01-03 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN102406617A (zh) * 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法
CN103002880A (zh) * 2010-06-09 2013-03-27 Abbvie公司 含有激酶抑制剂的固态分散体
CN103068232A (zh) * 2010-03-23 2013-04-24 西佳科技股份有限公司 多晶型物形式st-246和制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
PL1638938T3 (pl) 2003-06-20 2017-10-31 Siga Tech Inc Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
WO2012122279A1 (en) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
KR102000312B1 (ko) * 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
CN105307636A (zh) 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053778A1 (en) * 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
US20080004452A1 (en) * 2003-06-20 2008-01-03 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20070003516A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of poxvirus infections
CN103068232A (zh) * 2010-03-23 2013-04-24 西佳科技股份有限公司 多晶型物形式st-246和制备方法
CN103002880A (zh) * 2010-06-09 2013-03-27 Abbvie公司 含有激酶抑制剂的固态分散体
CN102406617A (zh) * 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DOUGLAS W GROSENBACH,等: "Development of the small-molecule antiviral ST-246 as a smallpox therapeutic", 《FUTURE VIROLOGY》 *
JENS T.CARSTENSEN: "《现代药用粉体微粒学》", 31 October 2004, 中国医药科技出版社 *
潘卫三: "《工业药剂学 第2版》", 31 March 2013, 高等教育出版社 *
罗明生,等: "《药剂辅料大全》", 31 January 2006, 四川出版集团·四川科学技术出版社 *
罗杰英,等: "《现代物理药剂学理论与实践》", 31 May 2007, 上海科学技术文献出版社 *
董铭心,等: "替韦立马一水合物的制备及新晶型结构测定", 《中国新药杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107126419A (zh) * 2016-02-26 2017-09-05 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
CN115141136A (zh) * 2021-03-31 2022-10-04 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法
CN115141136B (zh) * 2021-03-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法

Also Published As

Publication number Publication date
CA3246369A1 (en) 2025-10-30
IL242331B (en) 2021-02-28
EP3763702A1 (en) 2021-01-13
US9670158B2 (en) 2017-06-06
EP3021836A4 (en) 2016-12-07
CA2917199C (en) 2021-08-31
CA2917199A1 (en) 2015-01-22
EP3021836A1 (en) 2016-05-25
WO2015009566A1 (en) 2015-01-22
JP2016527229A (ja) 2016-09-08
JP2023080234A (ja) 2023-06-08
JP2021028336A (ja) 2021-02-25
US10045963B2 (en) 2018-08-14
US20160152565A1 (en) 2016-06-02
AU2014290333B2 (en) 2018-11-08
US20170224661A1 (en) 2017-08-10
WO2015009566A8 (en) 2015-12-10
JP6843616B2 (ja) 2021-03-17
JP7681393B2 (ja) 2025-05-22
EP3763702B1 (en) 2023-12-13
US20180125819A1 (en) 2018-05-10
EP3021836B1 (en) 2020-10-07
AU2014290333A1 (en) 2015-12-03
CN111635353A (zh) 2020-09-08
CA3128535C (en) 2024-10-15
US9889119B2 (en) 2018-02-13
CA3128535A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
JP7681393B2 (ja) アモルファステコビリマット調製
US8802714B2 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20080004452A1 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104758281A (zh) 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
EP2192901A2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
JP6564514B2 (ja) テコビリマットの調製方法
Wang et al. Discovery and development of VV116: a novel oral nucleoside anti‐SARS‐CoV‐2 drug
AU2012268859B2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN109651253B (zh) 苯丙烯酸酯衍生物及其作为神经保护药物的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160203

RJ01 Rejection of invention patent application after publication